Cempra to Present at Three Upcoming Investor Conferences
September 01 2016 - 7:30AM
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in
the treatment of bacterial infectious diseases, today announced it
will be participating in three upcoming investor conferences.
- Baird Global Healthcare Conference - 2016, The New York Palace
Hotel, New York, September 8, 2016 at 3:10 p.m. EDT.
- Morgan Stanley Global Healthcare Conference, the Grand Hyatt
Hotel, New York, September 12, 2016 at 1:05 p.m. EDT.
- Ladenburg Thalmann 2016 Healthcare Conference, Sofitel Hotel,
New York, September 27, 2016 at 12:00 p.m. EDT
A live audio webcast and archive of the presentations will be
available on the company website at
http://investor.cempra.com/events.cfm. Listeners are encouraged to
visit the site prior to the scheduled presentation to register,
download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical
company focused on developing antibiotics to meet critical medical
needs in the treatment of bacterial infectious diseases. Cempra's
two lead product candidates are currently in advanced clinical
development. Solithromycin has been successfully evaluated in two
Phase 3 clinical trials for community acquired bacterial pneumonia
(CABP) and applications for approval for both intravenous and oral
capsule formulations have been accepted for review by the FDA and
the EMA. Solithromycin is licensed to strategic commercial partner
Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings
Corporation, for certain exclusive rights in Japan. Solithromycin
is also in a Phase 3 clinical trial for uncomplicated urogenital
urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is
contracted with BARDA for the development of solithromycin for
pediatric use. Three formulations, intravenous, oral capsules and a
suspension formulation are in a Phase 1b trial in children from
birth to 17 years of age. Fusidic acid is Cempra's second product
candidate, which is being developed for acute bacterial skin and
skin structure Infections (ABSSSI) and is also in an exploratory
study for chronic oral treatment of refractory infections in bones
and joints. Both products seek to address the need for new
treatments targeting drug-resistant bacterial infections in the
hospital and in the community. Cempra has also synthesized novel
macrolides for non-antibiotic uses such as the treatment of chronic
inflammatory diseases, endocrine diseases and gastric motility
disorders. Cempra was founded in 2006 and is headquartered in
Chapel Hill, N.C. For additional information about Cempra please
visit www.cempra.com.
Company Contact:
John Bluth
Cempra, Inc.
+1 984 209 4534
jbluth@cempra.com
Investor Contact:
Robert Uhl
Westwicke Partners, LLC
+1 858 356 5932
robert.uhl@westwicke.com
Media Contact:
Melyssa Weible
Elixir Health PR
+1 201 723 5805
mweible@elixirhealthpr.com
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024